Compare ASM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASM | ABUS |
|---|---|---|
| Founded | 1968 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.0M | 839.5M |
| IPO Year | 2005 | 2008 |
| Metric | ASM | ABUS |
|---|---|---|
| Price | $5.62 | $4.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $8.18 | $5.00 |
| AVG Volume (30 Days) | ★ 3.1M | 2.7M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $53.35 | N/A |
| Revenue Next Year | $34.26 | $239.71 |
| P/E Ratio | $67.93 | ★ $5.14 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $3.10 | $3.25 |
| 52 Week High | $11.99 | $5.38 |
| Indicator | ASM | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 43.60 |
| Support Level | $5.44 | $4.16 |
| Resistance Level | $5.87 | $4.69 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 29.30 | 11.95 |
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.